OBJECTIVES: To determine the role of a serotonin 2A receptor gene (=HTR2A) variant in the development of impulse control and repetitive behaviors in Parkinson's disease. METHODS: We performed a genetic association analysis to a cohort of 404 Korean patients with Parkinson's disease who had been enrolled in a previous study. Presence of impulse control and repetitive behaviors was screened using modified version of Minnesota Impulsive Disorders Interview and genotyping for HTR2A c.102T > C was performed using the TaqMan assay. RESULTS: The T allele, which is presumably linked to higher receptor expression, was marginally associated with impulse control and repetitive behaviors in Parkinson's disease; the genetic influence was significantly enhanced in the lower levodopa-equivalent-dose group, increasing the risk by 2.8 and 6.9 times in CT and TT carriers, respectively (p-trend = 0.011). There was no significant interaction between the c.102T > C variant and clinical risk variables such as sex, age at onset, total daily levodopa-equivalent-dose, use of dopamine agonist and daily dose of dopamine agonist. CONCLUSION: Our data support a possible contribution of genetic variation in the HTR2A to the susceptibility to impulse control and repetitive behaviors in Parkinson's disease.
OBJECTIVES: To determine the role of a serotonin 2A receptor gene (=HTR2A) variant in the development of impulse control and repetitive behaviors in Parkinson's disease. METHODS: We performed a genetic association analysis to a cohort of 404 Korean patients with Parkinson's disease who had been enrolled in a previous study. Presence of impulse control and repetitive behaviors was screened using modified version of Minnesota Impulsive Disorders Interview and genotyping for HTR2A c.102T > C was performed using the TaqMan assay. RESULTS: The T allele, which is presumably linked to higher receptor expression, was marginally associated with impulse control and repetitive behaviors in Parkinson's disease; the genetic influence was significantly enhanced in the lower levodopa-equivalent-dose group, increasing the risk by 2.8 and 6.9 times in CT and TT carriers, respectively (p-trend = 0.011). There was no significant interaction between the c.102T > C variant and clinical risk variables such as sex, age at onset, total daily levodopa-equivalent-dose, use of dopamine agonist and daily dose of dopamine agonist. CONCLUSION: Our data support a possible contribution of genetic variation in the HTR2A to the susceptibility to impulse control and repetitive behaviors in Parkinson's disease.
Authors: Emke Maréchal; Benjamin Denoiseux; Ellen Thys; David Crosiers; Barbara Pickut; Patrick Cras Journal: J Neurol Date: 2014-05-14 Impact factor: 4.849
Authors: Julia Kraemmer; Kara Smith; Daniel Weintraub; Vincent Guillemot; Mike A Nalls; Florence Cormier-Dequaire; Ivan Moszer; Alexis Brice; Andrew B Singleton; Jean-Christophe Corvol Journal: J Neurol Neurosurg Psychiatry Date: 2016-04-13 Impact factor: 10.154
Authors: T Celeste Napier; Jean-Christophe Corvol; Anthony A Grace; Jamie D Roitman; James Rowe; Valerie Voon; Antonio P Strafella Journal: Mov Disord Date: 2014-12-05 Impact factor: 10.338